The Compton Capital Management Inc. RI Sells 85 Shares of Celgene Corporation (CELG)

The Compton Capital Management Inc. RI Sells 85 Shares of Celgene Corporation (CELG)

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Diversified Trust Co increased its position in shares of Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 9 shares during the period. Quadrant Capital Group LLC increased its position in shares of Celgene Corporation by 0.8% in the first quarter. Quadrant Capital Group LLC now owns 4,073 shares of the biopharmaceutical company’s stock worth $492,000 after buying an additional 34 shares during the period. Cadence Bank NA increased its position in shares of Celgene Corporation by 0.6% in the first quarter. Cadence Bank NA now owns 7,496 shares of the biopharmaceutical company’s stock worth $933,000 after buying an additional 45 shares during the period. Washington Trust Bank increased its position in shares of Celgene Corporation by 1.3% in the first quarter. Washington Trust Bank now owns 3,613 shares of the biopharmaceutical company’s stock worth $450,000 after buying an additional 46 shares during the period. Finally, Private Capital Advisors Inc. increased its position in shares of Celgene Corporation by 0.3% in the first quarter. Private Capital Advisors Inc. now owns 15,050 shares of the biopharmaceutical company’s stock worth $1,873,000 after buying an additional 50 shares during the period. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Compton Capital Management Inc. RI reduced its position in shares of Celgene Corporation (NASDAQ:CELG) by 0.3% during the first quarter, Holdings Channel reports. The firm owned 29,360 shares of the biopharmaceutical company’s stock after selling 85 shares during the period. Celgene Corporation makes up about 1.8% of Compton Capital Management Inc. RI’s holdings, making the stock its 11th largest position. Compton Capital Management Inc. RI’s holdings in Celgene Corporation were worth $3,653,000 as of its most recent filing with the SEC.

Celgene Corporation (CELG) opened at 135.18 on Wednesday. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $139.00. The firm has a market cap of $105.76 billion, a PE ratio of 41.86 and a beta of 1.89. The firm has a 50-day moving average price of $132.00 and a 200 day moving average price of $123.32.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same period in the previous year, the business earned $1.44 earnings per share. The company’s revenue was up 18.7% on a year-over-year basis. Equities research analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.

A number of research analysts have commented on the company. Jefferies Group LLC set a $154.00 target price on Celgene Corporation and gave the company a “buy” rating in a research note on Saturday, May 13th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their target price for the company from $96.93 to $131.70 in a research note on Friday, June 30th. Cann restated a “buy” rating and issued a $175.00 target price on shares of Celgene Corporation in a research note on Tuesday. Robert W. Baird restated an “outperform” rating and issued a $162.00 target price on shares of Celgene Corporation in a research note on Monday, May 22nd. Finally, SunTrust Banks, Inc. set a $150.00 target price on Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and twenty-three have issued a buy rating to the company’s stock. Celgene Corporation has an average rating of “Buy” and an average price target of $147.06.

In other news, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares in the company, valued at $481,200.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 227,755 shares of company stock valued at $30,368,142. Company insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Related posts

Leave a Comment